|
|
Article: Anadys Pharmaceuticals and LG Life Sciences Report Results From Completed Phase I/II Clinical Trial of ANA380 (LB80380) for Hepatitis B.
- Article from:
- PR Newswire
- Article date:
- November 1, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Data Presented at AASLD Annual Meeting in Boston Show Safety and Viral Load Reduction in Treated HBV Patients
Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd. (KOSPI: 68870) reported results from a recently completed Phase I/II clinical trial of ANA380 (LB80380), an orally available compound for the treatment of hepatitis B virus (HBV) infection, at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting yesterday in Boston.
In a presentation entitled "Phase I/II Double-Blind, Randomized, Placebo-Controlled Study of the Novel Anti-HBV Agent LB80380/ANA380 in Patients with Chronic HBV Infection," Dr. Man-Fung Yuen of ...